Investment summary

In 2011 Ark Therapeutics achieved two key objectives in its three-step business transformation strategy: securing new manufacturing contracts (with PsiOxus Therapeutics and Glasgow University) and selling the woundcare business. The focus is now on securing further long-term contracts for its Finnish GMP biological manufacturing facility and partners for its pipeline of gene therapies and small molecules. The first programme likely to be partnered is Ark's preclinical small molecule NRP-1 antagonist with potential to treat multiple solid tumours; a deal is expected in 2012.

Last updated on 23/04/2012

Industry outlook

The overall field of gene therapy remains relatively active despite a number of late-stage failures in recent years. This suggests a number of opportunities for Ark, in terms of potential pipeline development partners, as well as companies and academic institutions requiring manufacturing expertise and capabilities. The sole clinical-stage NRP-1 antagonist, Roche's RG7347 (MNRP1685) antibody, has been discontinued.

Last updated on 23/04/2012